Sartorius acquires cell culture specialist Xell AG
Extension of the Sartorius cell culture media business with a focus on media for gene therapeutics and vaccines
Sartorius, through its subgroup Sartorius Stedim Biotech, acquired cell culture specialist Xell AG headquartered in Bielefeld, Germany. Xell AG develops, produces, and markets media and feed supplements for cell cultures, especially for manufacturing viral vectors that are used in gene therapeutics and vaccines. Beyond these media, the company offers various analytical services for characterizing, screening, and quantifying media components, as well as for optimizing media composition.
Symbolic image
Constantin Wenning on Unsplash
Xell AG has so far been privately owned, employs around 35 people, and is expected to generate sales revenue of approximately 5 million euros at strong growth rates and a substantial two-digit EBITDA margin for the full year of 2021. Recently, a major state-of-the-art capacity expansion was completed at the company's headquarters. The contractual parties agreed on a purchase price of around 50 million euros in addition to two earn‑out components contingent upon the achievement of defined revenue targets in 2022 to 2025.
“With this acquisition, we are expanding our current media offering specifically by specialized media for manufacturing viral vectors and, additionally, in the area of media analytics. At the same time, we are accelerating the expansion of our production network in this fast-growing area,” said René Fáber, a member of the Sartorius Executive Board and Head of the Bioprocess Solutions Division. “I would like to cordially welcome the Xell team to Sartorius and am looking forward to our collaboration in this demanding time.”
Most read news
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Sartorius completes acquisition of Novasep’s chromatography division - Sales revenue forecast for 2022 updated due to acquisition
Scientists use quantum biology, AI to sharpen genome editing tool - "This study represents an exciting advancement toward, understanding how we can avoid making costly ‘typos’ in an organism’s genetic code"
New dyes detect disease through heartbeat signals
New protocol enables analysis of metabolic products from fixed tissues
Analytica USA: Expert knowledge for research and practice - Special show Digital Transformation: a hands-on Smart Lab
Keeping a cell’s powerhouse in shape
CRISPR-edited C. elegans identifies vulnerabilities in cancer
Detecting CRISPR/Cas gene doping - An initial step toward a test to pinpoint athletes trying to gain an unfair advantage